Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$29.7 million.

  • Tonix Pharmaceuticals Holding's Free Cash Flow fell 5812.87% to -$29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.3 million, marking a year-over-year decrease of 1030.78%. This contributed to the annual value of -$61.0 million for FY2024, which is 4445.3% up from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Free Cash Flow of -$29.7 million as of Q3 2025, which was down 5812.87% from -$15.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Free Cash Flow registered a high of -$9.9 million during Q2 2024, and its lowest value of -$36.7 million during Q1 2023.
  • Its 3-year average for Free Cash Flow is -$21.1 million, with a median of -$18.8 million in 2024.
  • In the last 5 years, Tonix Pharmaceuticals Holding's Free Cash Flow surged by 6065.76% in 2024 and then tumbled by 5812.87% in 2025.
  • Tonix Pharmaceuticals Holding's Free Cash Flow (Quarter) stood at -$22.8 million in 2023, then surged by 35.76% to -$14.6 million in 2024, then plummeted by 103.27% to -$29.7 million in 2025.
  • Its last three reported values are -$29.7 million in Q3 2025, -$15.4 million for Q2 2025, and -$16.6 million during Q1 2025.